A groundbreaking study presented at ASCO reveals that AstraZeneca’s experimental pill camizestrant, when used based on blood test results, can halve the risk of breast cancer progression or death—potentially reshaping treatment for patients with hormone receptor-positive, HER2-negative breast cancer
AstraZeneca’s experimental drug camizestrant significantly reduced the risk of disease progression or death in patients with advanced hormone receptor-positive, HER2-negative breast cancer by 56%, when prescribed based on early blood test results rather than visible tumor growth, experts announced Sunday at the American Society of Clinical Oncology (ASCO) meeting in Chicago.
The international trial marks a major shift in cancer treatment strategy by using liquid biopsy—a blood test that detects ESR1 gene mutations indicating early resistance to standard hormone therapies. Camizestrant, a selective estrogen receptor degrader (SERD), was shown to be effective in patients with early treatment resistance, even before tumors could be detected via imaging.
“This is going to be very impactful for our patients,” said Dr. Hope Rugo, head of breast medical oncology at City of Hope, California. “We’re staying ahead of the curve rather than reacting after the disease has already progressed,” added Dr. Eleonora Teplinsky, another ASCO expert.
The Phase 3 clinical trial involved 3,256 women, all previously treated with aromatase inhibitors and CDK4/6 inhibitors like Pfizer’s Ibrance or Novartis’ Kisqali. Among them, 315 women who developed ESR1 mutations were selected for a randomized trial. Those who switched to camizestrant plus CDK4/6 inhibitors experienced a median 16 months of progression-free survival compared to 9.2 months in the control group that continued standard therapy.
Camizestrant is not yet FDA-approved, but based on these findings, it may soon be adopted as part of a new treatment paradigm for early intervention in breast cancer progression.
AstraZeneca CEO Pascal Soriot acknowledged that integrating liquid biopsy into routine practice would initially be challenging but emphasized it as the future of cancer care.
In a separate announcement at the same ASCO meeting, another AstraZeneca drug, Imfinzi (durvalumab), showed promise in improving outcomes for early-stage stomach and esophageal cancer patients. When added to chemotherapy before and after surgery, Imfinzi reduced the risk of cancer recurrence, progression, or death by 29%.
Both sets of results were published in the New England Journal of Medicine and are expected to have lasting implications for the future of oncology.
Alphabet Inc., the parent company of Google, is entering the U.S. dollar and euro debt markets with a multi-tranche senior unsecured notes issue....
The eastern Ukrainian city of Pokrovsk has emerged as a critical point in Russia’s campaign to seize the remaining Ukrainian-held parts of Donetsk, ...
Italian emergency services were battling on Monday to rescue a Romanian worker trapped for hours under rubble following the partial collapse of a medi...
Tanzania's President Samia Suluhu Hassan vowed on Monday to move on from deadly protests set off by last week's disputed election as she was sworn int...
Russia said on Monday that its troops had advanced in the eastern Ukrainian city of Pokrovsk, a transport and logistics hub that they have been trying...
Alphabet Inc., the parent company of Google, is entering the U.S. dollar and euro debt markets with a multi-tranche senior unsecured notes issue.
The eastern Ukrainian city of Pokrovsk has emerged as a critical point in Russia’s campaign to seize the remaining Ukrainian-held parts of Donetsk, and its fate could shape the course of the conflict in the region.
Italian emergency services were battling on Monday to rescue a Romanian worker trapped for hours under rubble following the partial collapse of a medieval tower in central Rome, near the Colosseum.
A British man accused of carrying out a mass stabbing on board a train on Saturday was charged on Monday with 11 counts of attempted murder, including over a separate incident earlier the same day at a train station in east London.
Ukraine’s top military commander has confirmed that troops are facing “difficult conditions” defending the strategic eastern town of Pokrovsk against a multi-thousand Russian force.
Russia said on Monday that its troops had advanced in the eastern Ukrainian city of Pokrovsk, a transport and logistics hub that they have been trying to capture for over a year, but Ukraine said its forces were holding on.
Russia has launched its new nuclear-powered submarine, the Khabarovsk, at the Sevmash shipyard in Severodvinsk, the Defence Ministry said Saturday.
A man and a woman were killed and several others injured in a shooting on the Greek island of Crete on Saturday, in what police officials described as a family vendetta, reviving memories of the island’s long and complex history of inter-family violence.
U.S. President Donald Trump said he does not believe the United States is going to war with Venezuela despite growing tensions, though he suggested President Nicolás Maduro’s time in power may be nearing its end.
A prostate cancer blood test has been shown to reduce the risk of dying from the disease by 13% over two decades, researchers say.
Serious cases of a disorder of the large intestine are surging among Americans younger than 50, researchers say.
Russian President Vladimir Putin asked North Korean Foreign Minister Choe Son Hui during talks in the Kremlin on Monday to tell her country's leader Kim Jong Un that everything was "going to plan" in bilateral relations.
U.S. border czar says fentanyl should be considered a WMD.
U.S. states this week warned food aid recipients that their benefits may not be distributed in November if the federal government shutdown stretches into its fourth week.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment